Company Focus
Vertex Pharmaceuticals
Latest Vertex Pharmaceuticals News
Pharmaceutical
Significant news last week included Vertex Pharmaceuticals dropping development of its acute pain candidate VX-993 following a Phase II trial miss. Health and Human Services (HHS) Secretary Robert F Kennedy Jr continued his vaccine skepticism, announcing a wind-down in funding for mRNA vaccines. USA-based Eledon Pharmaceuticals released encouraging early trial results on its tegoprubart in renal transplantation. Also, US pharma major Eli Lilly reported new data on its investigational obesity drug orforglipron that failed to show a benefit over a rival candidate from Novo Nordisk. 10 August 2025
Related News
Insights
Company Spotlight
A California-based biotech company aiming to deliver a new class of RNA therapeutics.
Latest News & Features of interest to Vertex Pharmaceuticals
Pharmaceutical
Ipsen has reported second-quarter 2025 sales of 901 million euros ($980 million), up 8% from the same period a year ago. Core earnings per share rose 27% to 6.07 euros ($6.60) as strength in rare disease products offset flat performance in oncology. 31 July 2025
Biotechnology
Apellis Pharmaceuticals has received clearance from the American medicines regulator for Empaveli (pegcetacoplan) as the first treatment to reduce proteinuria in patients aged 12 and older with C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). 30 July 2025
Pharmaceutical
GSK posted a 6% rise in second-quarter sales to £8 billion ($10.7 billion), ahead of analyst forecasts. Pre-tax profits climbed 37% to £1.9 billion, while core earnings per share increased 15% to 46.5p, supported by strength in specialty medicines and vaccines. 30 July 2025
Biotechnology
The UK’s National Institute for Health and Care Excellence (NICE) has issued a positive recommendation for the use of AstraZeneca’s Imfinzi (durvalumab) in combination with Imjudo (tremelimumab) as a treatment option for adult patients with advanced or unresectable hepatocellular carcinoma (HCC). 30 July 2025
Pharmaceutical
USA-based Madrigal Pharmaceuticals today announced that it has entered into an exclusive global license agreement with CSPC Pharmaceutical for SYH2086, a pre-clinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist and orforglipron derivative. 30 July 2025
Biotechnology
US AI-focused start-up Formation Bio and IMIDomics, a precision medicine company focused on immune-mediated inflammatory diseases today announced that Formation Bio has licensed worldwide rights to IMIDomics' first-in-class anti-CD226 monoclonal antibody (MAb). 30 July 2025
Pharmaceutical
Shares of DURECT Corporation shot up 240% to $1.88 by close of trading Tuesday, after Canada’s Bausch Health agreed to acquire the Cupertino, California-based liver drug developer for an upfront cash payment of $1.75 per share. 30 July 2025
Pharmaceutical
Swiss pharma company Idorsia today released encouraging first half 2025 financial results, sending its shares up 8.5% to 2.94 francs in early trading. 30 July 2025
Biotechnology
ReAlta Life Sciences, a US biopharma seeking to address life-threatening rare and acute inflammatory diseases by rebalancing the inflammatory response, has announced the appointment of Ellen Lubman as chief business officer (CBO). 29 July 2025
Biotechnology
Privately-held Italian pharma company Alfasigma has announced positive topline results from the OLINGUITO Phase III trial of filgotinib in active axial spondyloarthritis (axSpA). 29 July 2025
Latest In Brief for Vertex Pharmaceuticals
Biosimilars
Hungarian drugmaker Gedeon Richter has announced that the European Commission has granted marketing authorization for the biosimilar denosumab products Junod and Yaxwer. 2 July 2025
Latest Relevant Ones To Watch News
UK and USA-listed PureTech Health today announced the launch of a new founded entity to be called Celea Therapeutics. 12 August 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze